Rokit Healthcare Signs CKD Prediction AI Licensing Agreement with Saudi LifeHope

20% Royalty on Net Sales Structure

Rokit Healthcare announced on May 7 that it has signed a technology licensing agreement with Saudi Arabian medical company LifeHope for its artificial intelligence (AI) algorithm that predicts chronic kidney disease (CKD).

Rokit Healthcare company logo image. Rokit Healthcare

Under the agreement, Rokit Healthcare will provide its CKD prediction AI algorithm for integration into LifeHope’s ‘Longevity platform.’ The license is non-exclusive and non-transferable, and its application is limited to Saudi Arabia. Rokit Healthcare will receive a 20% royalty on the net sales generated from the platform. The algorithm will be provided in object code form, excluding core technologies such as source code, datasets, and the AI architecture.

LifeHope is the owner of the Albayat Medical Tower located in Riyadh, Saudi Arabia. The company plans to introduce the platform in connection with the hospital network and insurance benefits system within the Saudi healthcare system.

The prevalence of chronic kidney disease in Saudi Arabia is estimated to be around 4.76%, with the number of patients estimated at between 1.2 million and 1.7 million. If high-risk groups such as those with diabetes and hypertension are included, the potential target market could expand further.

Starting with this contract, Rokit Healthcare plans to pursue expansion into Gulf Cooperation Council (GCC) countries, including the United Arab Emirates (UAE), Qatar, and Kuwait.

A representative from LifeHope stated, “The Saudi government is providing significant support for the prevention and diagnosis of kidney disease,” adding, “This is the first time a function to predict five years ahead has been introduced.”

This content was produced with the assistance of AI translation services.